{"database":"ecrin-mdr-crc","file_versions":[],"scores":null,"additional":{"omics_type":["Clinical"],"study_start_year":["2013"],"condition":["locally advanced rectal cancer"],"disease":["Locally Advanced Rectal Cancer"],"study_type":["Interventional"],"full_dataset_link":["https://newmdr.ecrin.org/Study/2625365"],"location":["Japan"],"study_start_month":["2"],"repository":["ECRIN MDR"],"study_status":["Completed"],"additional_accession":[]},"is_claimable":false,"name":"Phase I/II study of preoperative treatment with capecitabine, oxaliplatin and irinotecan (XELOXIRI) in patients with advanced colorectal cancer","description":"Interventions: Neo-adjuvant chemotherapy : XELOXIRI 6 cycles Resection : total mesorectal excision or tumor-specific mesorectal excision Adjuvant chemotherapy : XELOX 4 cycles\nPrimary outcome(s): 1) Phase I To determine the recommended dose 2) Phase II pathological complete response rate\nStudy Design: Single arm Non-randomized","dates":{"creation":"2013-02-15"},"accession":"2625365","cross_references":{"Japan Primary Registries Network":["JPRN-UMIN000009974"]}}